Top 2 Health Care Stocks That May Plunge This Month

Two healthcare stocks, Esperion Therapeutics (ESPR) and Nuvation Bio (NUVB), are flashing high Relative Strength Index (RSI) values of 85.7 and 81.8 respectively, indicating they are significantly overbought. This occurs despite Esperion reporting better-than-expected Q2 results with 42% year-over-year sales growth, and Nuvation Bio initiating rapid commercialization post-FDA approval, both experiencing stock gains exceeding 40% in the past month. The elevated RSI levels suggest a potential warning for momentum-driven investors, implying a possible short-term reversal or consolidation despite recent positive company developments.

Analysis

Esperion Therapeutics (ESPR) and Nuvation Bio (NUVB) are exhibiting classic signs of being technically overbought, presenting a potential conflict for investors weighing strong fundamental news against momentum indicators. ESPR's stock has surged approximately 56% in the past month, pushing its Relative Strength Index (RSI) to 85.7, well above the 70 threshold for an overbought condition. This rally is underpinned by a strong second quarter, where the company exceeded financial expectations and reported a 42% year-over-year increase in net U.S. product sales. Similarly, NUVB has gained around 44% over the same period, reaching an RSI of 81.8. This price appreciation follows its successful transition to a commercial-stage company post-FDA approval for IBTROZI, having already treated 70 patients in seven weeks. Despite NUVB posting an in-line loss, the market has responded positively to this commercial milestone, pushing the stock to $3.42, just shy of its $3.48 52-week high. The elevated RSI levels for both companies signal that the recent powerful rallies may be overextended, suggesting a heightened risk of a near-term pullback or consolidation, even as their underlying business narratives remain positive.

Key Decisions for Investors

• Given the high RSI values for both ESPR (85.7) and NUVB (81.8), momentum-focused investors should consider trimming positions or setting tight stop-losses to protect the significant recent gains from a potential short-term reversal.
• For fundamentally-driven investors, any technical pullback could represent a more attractive entry point, particularly for ESPR, given its demonstrated commercial execution and 42% year-over-year sales growth.
• Investors in NUVB should monitor initial sales data for IBTROZI closely, as the stock's price near its 52-week high suggests market expectations for a successful commercial launch are already significantly priced in.
• The divergence between positive fundamental catalysts and overbought technical signals warrants caution; assess whether the recent 44-56% monthly gains have fully priced in the positive developments before initiating new long positions.